- Home
- SER vs BYSI Comparison
SER vs BYSI Comparison
Compare SER & BYSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SER
- BYSI
- Stock Information
- Founded
- SER 2017
- BYSI 2010
- Country
- SER United States
- BYSI United States
- Employees
- SER N/A
- BYSI N/A
- Industry
- SER Biotechnology: Pharmaceutical Preparations
- BYSI Biotechnology: Pharmaceutical Preparations
- Sector
- SER Health Care
- BYSI Health Care
- Exchange
- SER Nasdaq
- BYSI Nasdaq
- Market Cap
- SER 56.5M
- BYSI 71.0M
- IPO Year
- SER 2018
- BYSI 2017
- Fundamental
- Price
- SER $5.75
- BYSI $1.70
- Analyst Decision
- SER Strong Buy
- BYSI
- Analyst Count
- SER 1
- BYSI 0
- Target Price
- SER $11.00
- BYSI N/A
- AVG Volume (30 Days)
- SER 10.4K
- BYSI 19.6K
- Earning Date
- SER 05-08-2025
- BYSI 05-12-2025
- Dividend Yield
- SER N/A
- BYSI N/A
- EPS Growth
- SER N/A
- BYSI N/A
- EPS
- SER N/A
- BYSI N/A
- Revenue
- SER $51,000.00
- BYSI N/A
- Revenue This Year
- SER N/A
- BYSI N/A
- Revenue Next Year
- SER N/A
- BYSI N/A
- P/E Ratio
- SER N/A
- BYSI N/A
- Revenue Growth
- SER N/A
- BYSI N/A
- 52 Week Low
- SER $3.81
- BYSI $0.98
- 52 Week High
- SER $14.57
- BYSI $2.97
- Technical
- Relative Strength Index (RSI)
- SER 54.81
- BYSI 52.00
- Support Level
- SER $5.01
- BYSI $1.63
- Resistance Level
- SER $6.00
- BYSI $1.77
- Average True Range (ATR)
- SER 0.32
- BYSI 0.08
- MACD
- SER 0.01
- BYSI -0.01
- Stochastic Oscillator
- SER 81.65
- BYSI 53.33
About SER Serina Therapeutics Inc.
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The Company has one reportable segment relating to the research and development of its POZ platform.
About BYSI BeyondSpring Inc.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment.